 Arana Therapeutics Limited Company Summary
|
| Undertake research, development, production, formulation and marketing of peptides, and related products for the the pharmaceutical, veterinary and agricultural industries. |
|
| Company Data |
 |
Fax |
(02) 9870 8786 |
|
|
Principal Sector |
Health & Pharm |
|
|
Principal Industry |
Biotechnology |
|
|
Listed |
1986/01/23 |
|
|
Homepage |
www.peptech.com |
|
| |
| Markets | | Stock Exchange | Stock Code |  ASX:AAH | AAH | | | |
|
|
| News |
|
|
|  Aust Business Headlines, (ASX: JBM), (ASX: PSV), (ASX: PTD) (OCT 29, 2007) | | Aust Market Wrap, (ASX: PTD), (ASX: EGX), (ASX: IAG), (ASX: OXR), (ASX: OXR), (ASX: SEV), (ASX: QAN), (ASX: CAA), (ASX: GBG) (JULY 9, 2007) |
| MultiMedia |
|
|
|  Arana Therapeutics Excellence In Biotechnology Investment - Mr John Chiplin, CEO, Arana Therapeutics (MAY 5, 2008) | | Peptech ASX: PTD - Shareholders Approve Peptech-Evogenix Merger - Dr John Chiplin, CEO (AUG 9, 2007) | | Peptech ASX: PTD - Peptech Presentation To Eg Capital Forum - Dr John Chiplin, CEO (JULY 12, 2007) | | Peptech ASX: PTD - Merger Roadshow Presentation - Dr John Chiplin, MD; Dr Phil Jennings, Exec. Director and Dr Cliff Holloway, VP of Bus. Development (JUNE 6, 2007) | | Peptech ASX: PTD - Enters Phase I Clinical Trials - Dr Phil Jennings, Executive Director (MAY 22, 2007) | | Peptech ASX: PTD - Record Profit for Half Year - Dr John Chiplin, MD (MAY 17, 2007) | | Peptech ASX: PTD - Peptech & EvoGenix Merge to Form Antibody Powerhouse - Dr John Chiplin and Dr Merilyn Sleigh (MAY 7, 2007) | | Peptech ASX: PTD - Suprelorin Recommendation Clears Path for Sales in Europe - Dr Paul Schober, General Manager, Peptech Animal Health (MAR 21, 2007) | | Peptech ASX: PTD - Appoints Global Financial Adviser to Examine Strategic Options - Dr John Chiplin, CEO (MAR 14, 2007) | | Peptech ASX: PTD - Company Update - Dr Cliff Holloway, Vice President, Business Development (FEB 9, 2007) | | Peptech ASX: PTD - Domantis Sale and AIM Listing - Dr John Chiplin, CEO (DEC 21, 2006) |
|
